Heterozygous germline mutations in PRKCSH cause autosomal dominant polycystic liver disease (PCLD), but it is not clear how they lead to cyst formation. We investigated whether mutations in cyst epithelial cells and corresponding loss of the PRKCSH gene product (hepatocystin) contributed to cyst development. METHODS: Liver cyst material was collected through laparoscopic cyst fenestration from 8 patients with PCLD who had a heterozygous germline mutation in PRKCSH. Tissue sections from 71 cysts (2-14 per patient) were obtained for hepatocystin staining and mutation analysis. Cyst epithelium was acquired using laser microdissection; DNA was isolated and analyzed for loss of heterozygosity (LOH) and somatic mutations using restriction analysis and sequencing. Common single nucleotide polymorphisms (SNPs) in a 70-kilobase region surrounding the germline mutation were used to determine variations in the genomic region with LOH. RESULTS: The wild-type allele of PRKCSH was lost (LOH) in 76% of cysts (54/71). Hepatocystin was not detected in cyst epithelia with LOH, whereas heterozygous cysts still expressed hepatocystin. The variation observed in the LOH region analysis indicates that cysts develop independently. We also detected somatic mutations in PRKCSH in 17% (2/12) of the cysts without LOH. Trans-heterozygous mutations in SEC63 were not observed. CONCLUSIONS: Among patients with PCLD who have a heterozygous germline mutation in PRKCSH, we found secondary, somatic mutations (second hits) in more than 76% of the liver cyst epithelia. PCLD is recessive at the cellular level, and loss of functional PRKCSH is an important step in cystogenesis.
A utosomal dominant polycystic liver disease (PCLD) is a genetic condition characterized by the presence of multiple fluid-filled hepatic cysts. These cysts cause a grossly enlarged liver with displacement of other abdominal organs. Patients experience abdominal pain, nausea, anorexia, and shortness of breath. 1 PCLD is a dominantly inherited disorder and so far 2 genes, PRKCSH 2, 3 and SEC63, 4 have been associated with the disease. These genes encode for hepatocystin and SEC63, respectively, which are both endoplasmic reticulum (ER) resident proteins, widely expressed in most cell types including hepatocytes and cholangiocytes. 5 Hepatocystin is assembled as a heterodimer complex, which acts to achieve proper topology and folding of membrane and secreted glycoproteins in the ER. SEC63 is believed to play a role in protein transport across the ER membrane. 6 How these proteins are involved in the development of polycystic livers remains unknown, and a better understanding of the initiating event underlying cyst formation would provide valuable insight into the pathogenesis.
Under physiologic conditions, maturation of the ductal plate leads to development of normal bile ducts. In PCLD, dense complexes of intralobular bile ductules remain intact and develop into cysts by disconnecting from the biliary tree through a process of differentiation and proliferation. 7 It has been speculated that cyst formation results from a focal process involving only a subset of cells. This theory implies that each cyst starts with a defining genetic event. 8 All known mutations in PCLD are heterozygous and affect only one allele of the gene while the other allele is normal (wild type). 9 Furthermore, in liver tissue sections from patients with a PRKCSH germline mutation, hepatocystin is normally expressed in both hepatocytes and cholangiocytes from normal bile ducts. In contrast, hepatocystin appears to be lacking from the cells most relevant to PCLD: cholangiocytes from liver cyst epithelium. 10 It is not known why cyst epithelium does not express hepatocystin and how this relates to the heterozygous state of the germline mutation in PCLD. Abnormal cholangiocyte growth and cyst formation could result from a dominant negative effect of the mutant PRKCSH on the expression or function of the wild-type allele in this tissue. Alternatively, the wild-type PRKCSH allele could be lost through somatic genomic mutations, consistent with the so-called 2-hit model. 11 To delineate the molecular mechanism underlining cyst formation in PCLD, we isolated cyst epithelium from patients with a PRKCSH germline mutation to identify possible somatic mutations. Our data suggests that the 2-hit model holds true for the primary manifestation of human PCLD and supports the hypothesis that PCLD is recessive on a cellular level.
Materials and Methods

Patient Material
We obtained whole blood and liver tissue samples from 8 patients with PCLD who underwent laparoscopic cyst fenestration because of severe symptoms. 12 All patients were female, and age at the time of surgery ranged between 35 and 54 years of age (median age, 41 years). We used formalin-fixed, paraffinembedded liver tissue samples that had routinely been collected for pathologic examination (n ϭ 22 from 3 patients) or fresh tissue samples that had been snap frozen immediately after excision and stored at Ϫ80°C until analysis (n ϭ 49 from 5 patients). All samples were collected with appropriate ethics approval, and written informed consent for the use of secondary tissue was obtained from all patients.
Genotyping
We screened patient DNA from whole blood for germline mutations in PRKCSH and SEC63 using direct sequencing as described previously. 9 In brief, DNA from whole blood was isolated using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN) and stored at 4°C. Exons and flanking intronic sequences were amplified using polymerase chain reaction with specific primers (Supplementary Table 1 ). The amplified fragments were purified (QIAEXII Gel Extraction Kit; Qiagen, Hilden, Germany) and sequenced with the BigDye Terminator Kit and ABI3730 capillary sequencer (Perkin-Elmer Applied Biosystems, Boston, MA).
Laser Microdissection
Tissue sections (10 m) from frozen or formalin-fixed, paraffin-embedded liver samples were mounted on cross-linked PEN membrane slides (Leica Microsystems GmbH, Wetzlar, Germany), stained with Mayer's hematoxylin (1 minute), and rinsed in tap water. Paraffin-embedded sections were deparaffinized using xylene and ethanol before hematoxylin nuclear stain. Specific isolation of the cyst epithelial cells (300 to 2000 cells/ sample) was performed using a Leica Laser Microdissection System (LMD 6000, Leica Microsystems GmbH) equipped with an UV laser (Leica Microsystems GmbH). 13 For each patient, we dissected liver cells (hepatocytes and other noncyst epithelial cells) to serve as a control sample.
DNA Isolation
DNA from the dissected cells was isolated using the QIAamp DNA Micro Kit (Qiagen) according to instructions and with the use of carrier RNA. To increase the DNA yield and quality from formalin-fixed tissue samples, we made the following adjustments: samples were digested at 56°C for 2 days with occasional agitation, proteinase K was added in 2 steps (5 L on day 1 and 5 L on day 2), and after digestion and addition of buffer ATL, samples were incubated at 90°C for 1 hour to promote reverse cross-linking of the DNA.
Loss of Heterozygosity Analysis in Cyst Epithelium
Loss of heterozygosity (LOH) was analyzed in all samples by amplifying the genomic region containing the germline mutation followed by digestion or sequencing (Supplementary Table 2 ).
Somatic Mutations and Region Analysis
We conducted the following analyses on DNA isolated from frozen tissue samples (Figure 1 ).
1. PRKCSH sequencing. In cysts without LOH, all PRKCSH coding exons and flanking intronic sequences were sequenced (as described for genotyping) to detect somatic mutations in DNA from the cysts. DNA isolated from whole blood of the patient was used as a reference sample. 2. To yield enough material for the LOH region analysis and SEC63 sequencing, cyst epithelial DNA was amplified using a commercially available whole genome amplification kit (GenomePlex WGA; Sigma, St Louis, MO) and purified (GenElute PCR Clean-Up Kit; Sigma) before analysis. Sample amplification was performed in duplicate to control for any mutations resulting from the whole genome amplification procedure. 3. LOH region analysis. For cysts displaying LOH, we used 5 common (no pathogenic) single nucleotide polymorphisms (SNPs) to analyze the genomic heterozygosity state in a 70-kilobase genomic region surrounding the PRKCSH locus (average heterozygosity between 0.4 and 0.5). Genomic regions were polymerase chain reaction amplified, followed by either restriction analysis (rs34095, rs311786, and rs311805) or sequencing (rs313624 and rs313624) (Supplementary Table 2 ). Only those SNPs that were homozygous in the germline of the patient were analyzed in the DNA derived from cyst epithelium. 4. SEC63 sequencing. To identify any somatic mutations in SEC63, we sequenced, in all frozen tissue samples, the SEC63 exons and flanking intronic sequences (as described for genotyping) on amplified cyst epithelial DNA.
Statistical Analysis
To calculate the 95% confidence interval of the proportion of cysts with LOH, we used the Newcombe-Wilson method for proportions without continuity correction (Supplementary Figure 1) . 14 
Immunohistochemistry
Tissue sections (7 m) for immunohistochemistry were obtained together with tissue sections for laser microdissection from the same cysts. Frozen sections were mounted on SuperFrost Plus glass slides (Thermo Scientific, Waltham, MA), allowed to dry at room temperature, and stored at Ϫ80°C or used directly. First, slides were washed in phosphate-buffered saline (PBS) and fixed in 4% formaldehyde/phosphate buffer for 30 minutes at room temperature. Endogenous peroxidase was blocked in 0.15% H 2 O 2 /Tris-buffered saline for 10 minutes, followed by Tris-buffered saline wash. Next, samples were microwave heated and boiled for 10 minutes in sodium citrate buffer, pH 6, cooled down to room temperature, and washed in PBS. Endogenous avidin/biotin was blocked (Vector Laboratories, Burlingame, CA), followed by overnight incubation with 1:200 mouse anti-hepatocystin antibody (sc10774; Santa Cruz Biotechnology, Santa Cruz, CA) in 1% bovine serum albumin/ PBS. After washing, tissue sections were incubated for 1 hour with secondary antibody (biotinylated anti-mouse immunoglobulin G; Vector Laboratories), washed, and bound to horseradish peroxidase using the ABC method (Vector Laboratories). Detection was performed with the use of diaminobenzidine tetrahydrochloride as substrate and enhanced with copper sulfate. Nuclei were counterstained with Mayer's hematoxylin.
Immunohistochemistry scoring was performed as described previously. Briefly, hepatocystin staining in cyst epithelium was compared with normal bile duct staining. Results were classified as negative (hepatocystin staining being absent from cyst epithelium) or positive (present). 10 
Results
Germline Mutations
We collected samples from 8 patients with a pathogenic PRKCSH mutation who also underwent laparoscopic cyst fenestration: 5 patients with a c.1341-2AϾG mutation and 3 patients with a c.292ϩ1GϾC mutation. Both germline mutations affect a PRKCSH splice site leading to a premature stop codon. 15 All PRKCSH mutations were present in a heterozygous state. No SEC63 germline mutations were detected in these patients.
Somatic LOH in Majority of PCLD Cysts
Somatic mutation analysis showed loss of the wild-type PRKCSH allele in 76% (54/71) of the laser-microdissected cysts (Figure 2A ). This in contrast to the surrounding liver tissue and blood of the patients, in which both the wild-type and mutated allele were still present. The percentage of cysts with LOH was comparable between the different patients, with the 95% confidence interval for all samples (n ϭ 71) ranging from 65% to 84% (Supplementary Figure 1) . To follow up on this finding, we continued with LOH region analysis and protein expression analysis and determined the role of additional somatic mutations in PRKCSH and SEC63 in frozen tissue samples (49 cysts; Figure 2A ). The laser-microdissected cysts from formalin-fixed, paraffin-embedded tissues (22 cysts; Figure 2A ) did not provide enough DNA of sufficient quality to perform the downstream analyses and were therefore excluded.
Genomic LOH Region Varies Between Different Cysts
We examined the genomic region surrounding the PRKCSH locus using 5 common SNPs encompassing a 70-kilobase region ( Figure 2B and C). Only informative SNPs (heterozygous in the germline of the patient) were analyzed in the cyst DNA samples. We found that 97% (36/37) of the cysts showing LOH at the site of the germline mutation had at least one neighboring homozygous SNP. Furthermore, in 65% (24/37) of the cysts, all informative SNPs were homozygous, indicating that LOH extended beyond the 70-kilobase region. We found both homozygous and heterozygous SNPs in 38% (14/37) of the cysts, suggesting that a genomic breakpoint occurred within this region.
Somatic Substitutions in PCLD Cyst Epithelium
In the 12 cysts without LOH, we sequenced all coding exons and flanking intronic PRKCSH sequences and identified a single base pair substitution in 2 heterozygous cysts from patient 1 ( Figure 3A and B) . This finding was confirmed by several independent experiments and no somatic mutations were identified in the control samples (patient blood and nonepithelial cells dissected from the same tissue), confirming the site-specific nature of this genomic event. Both mutations lead to the change of a conserved amino acid and are expected to affect protein function according to in silico analysis with PolyPhen, SIFT, and HOPE. 16, 17 In brief, phenylalanine at position 75 is highly hydrophobic and is predicted to be buried within the core of the protein. In case of the p.F75S mutation, phenylalanine will be replaced by serine, which causes a loss of hydrophobic interactions in the core of the protein. In addition, phenylalanine and serine differ in size, which will affect the structure and stability of the protein. For the p.C500Y mutation, cysteine is replaced by tyrosine. This cysteine is highly conserved at this position among a large range of species, highlighting its importance. Further, tyrosine is bigger than cysteine and probably will not fit in the core of the protein, thereby disrupting the structure of the protein. Lastly, loss of a cysteine residue often affects a disulfide bond.
Hepatocystin Expression
Hepatocystin expression was analyzed in 49 cysts using immunohistochemistry (Figure 3C and D) . This showed that hepatocystin was absent from cysts with LOH, indicating that the truncated gene product from the mutated allele is not produced or not recognized by the antibody. Interestingly, hepatocystin staining was still present in cysts without somatic mutations in PRKCSH and in the 2 cysts with acquired point mutations ( Figure  3A and B).
Trans-heterozygosity
Because germline mutations in PRKCSH and SEC63 are both associated with PCLD, it is possible that somatic SEC63 mutations contribute to cyst formation in cysts without somatic PRKCSH mutations. However, we 
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did not detect any somatic changes in the SEC63 sequence in DNA derived from cyst epithelium compared with nonepithelial cells or DNA from whole blood from the 49 cysts analyzed. We therefore exclude trans-heterozygous SEC63 mutations as a major cause of cyst formation in PRKCSH germline carriers.
Discussion
We set out to map the molecular events that occur in cyst epithelia from patients with PCLD. Our principal finding is that in patients with a heterozygous germline PRKCSH mutation, 76% (54/71) of the cysts lost the functional PRKCSH allele through LOH. The LOH region differed among cysts and extended beyond the 70-kilobase region in the majority (97%) of these cysts. We related the genomic data to immunohistochemical analysis of the tissue sections and found that cysts without LOH indeed still express hepatocystin. In addition, we sequenced the full PRKCSH gene in 12 cysts without LOH and found a somatic missense mutation in 2 cysts (17%; 2/12 cysts). Finally, we excluded the presence of trans-heterozygous SEC63 mutations, the other gene associated with PCLD.
Our data support the 2-hit mechanism for disease pathogenesis for the formation of cysts in PCLD ( Figure   4 ), which was originally described for mutations in tumor suppressor genes leading to inheritable cancers. 11 According to this model, genomic mutations naturally occur in a stochastic manner in each cell during life. For example, in familial adenomatous polyposis, somatic second-hit mutations in the APC gene have been associated with the formation of a polyp. Because these patients develop thousands of polyps in their intestine, the chance that a particular allele would be mutated (through LOH or other somatic mutations) was estimated to be approximately 1:500,000 per cell each year. 18 Although the exact number may vary based on the cell type and the gene involved, somatic PRKCSH mutations could lead in cholangiocytes to the formation of a liver cyst stem cell. Over time, this stem cell could develop through clonal expansion and secretion into a new cyst, in which all daughter cells carry the same genomic mutation. Because the percentage of cysts with a PRKCSH mutation is much higher than the random mutation frequency of a gene, we believe that loss of PRKCSH provides a strong selective pressure for these cells and, hence, the formation of a cyst. Because most people carry 2 functional alleles of PRKCSH, the chance that any cholangiocyte will randomly lose both alleles from the same gene would be extremely small. However, losing both alleles through somatic mutations may play a role in the formation of single liver cysts in the general population.
How loss of PRKCSH affects cell function and how this results in the formation of a cyst is not known. Although somatic second-hit mutations could lead to loss of PRKCSH anywhere in the body, it is remarkable that cyst formation is only seen in the liver. This suggests that the liver-specific phenotype of PCLD is caused by a cholangiocyte-specific response to loss of PRKCSH. It is therefore possible that PRKCSH plays an important role in the growth regulation of cholangiocytes and acts as a "tumor suppressor gene." However, malignancies have never been related to patients with PCLD.
Although liver cyst epithelium displays cholangiocyte properties, the initiating somatic hit could also have occurred in a liver progenitor cell, which may explain the proliferative characteristics of cysts. 19 The genetic pattern we discovered in cysts appears to be less variable than, for example, in colorectal adenomas, 20 but we cannot exclude that polyclonality or niche succession also plays a role in the formation of polycystic livers. 21 There are several examples of the second-hit mechanism in nonmalignant diseases, including autoimmune lymphoproliferative syndrome, 22 venous and glomuvenous malformations, 23 multi-cavernous cerebral cavernous malformations lesions, 24 and autosomal dominant polycystic kidney disease (ADPKD). [25] [26] [27] Polycystic kidneys are the primary presentation in AD-PKD, but some patients also develop polycystic livers similar to patients with PCLD. 28 ADPKD is caused by heterozygous germline mutations in PKD1 or PKD2, making ADPKD and PCLD genetically and phenotypically distinct disorders. Somatic mutation analysis in kidney and liver cysts of patients with ADPKD with a PKD1 germline mutation demonstrated LOH in 4% to 24% of kidney cysts 25,29 -31 and in 10% of liver cysts. 32 Additional somatic mutations were found in 17% of kidney cysts 31 and in 28% of liver cysts. 32 Even though PKD1 mutation analysis was hampered by technical difficulties, the proportion of kidney and liver cysts with somatic mutations was much higher compared with cysts from patients with PRKCSH, whereas the proportion of LOH was much lower. This also holds true for PKD2 mutated patients, in who somatic mutations were found in 15% to 64% of kidney cysts [33] [34] [35] and 11% of liver cysts, 34 whereas LOH was present in only 0 to 12% of kidney cysts [33] [34] [35] and in none of the 9 liver cysts analyzed. 34 One possible explanation for the difference between ADPKD and PCLD might be that the genomic region surrounding PRKCSH is more prone to LOH. Some regions in the DNA are known to be more susceptible to DNA double-strand breaks and misrepair. However, the region harboring PRKCSH is not a known hotspot for genomic rearrangements. Genomic mutations leading to LOH include deletions, translocations, or mitotic recombination, 36 but which mechanism causes LOH in PCLD cysts is not clear.
We found that the region with LOH varied greatly among the different cysts, even in those coming from the same patient. This is consistent with the idea that secondhit mutations occur randomly in the genome and supports the hypothesis that each cyst develops independently as the result of an independent somatic mutation. The presence of second hits in cysts from all patients with PCLD tested indicates that this is not a chance event limited to a single patient. The vast majority of cysts show LOH (76%), which indicates that LOH is the most likely mode of inactivation for this gene. The remaining 24% of cysts represent all the other mutations that may lead to cyst formation. We have detected missense PRKCSH mutations in 2 of the 12 cysts, but we may have missed PRKCSH mutations in the remaining cysts. Using exon sequencing, we will not detect exon spanning deletions or translocations, thereby underestimating the proportion of cysts with somatic mutations. In addition, methylation or mutations in regulatory sequences such as the promoter region may affect gene transcription of the wild-type PRKCSH allele. However, immunohistochemistry showed that hepatocystin was still expressed in the heterozygous cysts, suggesting that PRKCSH gene expression is not silenced in these cysts.
In addition, there may be modes of cyst formation involving other genes than PRKCSH. The concept of transheterozygosity as a 2-hit mechanism has precedence in ADPKD. 31, 35 In patients with a heterozygous germline mutation in PKD1 or PKD2, cysts can develop due to a second hit in the remaining allele of the same gene or due to a somatic mutation in one allele of the other ADPKD gene. The best candidate for trans-heterozygosity in PCLD is SEC63, the other gene known to be involved in PCLD. However, we did not detect any mutations in SEC63 and other candidates for trans-heterozygous mutations could include genes with a functional interaction to PRKCSH and other genes known to be involved in cytogenesis such as PKD1, PKD2, or PKHD1. 37, 38 The high proportion of cysts with loss of the PRKCSH wild-type allele suggests that somatic second-hit mutations, with consequent loss of hepatocystin, are an important step in cyst formation in PCLD. This finding is essential for our understanding of the molecular mechanism underlying cyst formation and shows that cholangiocytes are the primary affected cell type. It also indicates that PCLD is recessive at the cellular level, resulting from hepatocystin loss rather than hepatocystin haploinsufficiency. How loss of PKRCSH affects the cholangiocytes is not clear, but PRKCSH may hold some characteristics similar to tumor suppressor genes because loss of both copies of the gene is associated with cyst formation. 
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